<mets:mets OBJID="eprint_4316" LABEL="Eprints Item" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mets="http://www.loc.gov/METS/" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mets:metsHdr CREATEDATE="2026-07-05T10:00:16Z"><mets:agent ROLE="CUSTODIAN" TYPE="ORGANIZATION"><mets:name>Repositori BKPK</mets:name></mets:agent></mets:metsHdr><mets:dmdSec ID="DMD_eprint_4316_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:titleInfo><mods:title>Laporan Penelitian Studi Efikasi dan Keamanan Terapi Tambahan Obat Baricitinib pada Pasien Covid-19 (Uji Klinis Fase III, Acak, Terbuka, Perbandingan Pemberian Baricitinib dan Tocilizumab pada Pasien Covid-19 Derajat Barat)</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Tri</mods:namePart><mods:namePart type="family">Maharani</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Latar belakang : Saat ini angka mortalitas pasien Covid-19 di Indonesia 2,7% dan sebagian besar berasal dari pasien derajat berat. Pilihan terapi untuk pasien Covid-19 derajat berat masih terbatas, masih dalam tahap operational research (plasma konvalesens (PK), Tocillizumab (TCZ), immunoglobulin intravena (IVIG) dan stem cell).&#13;
TCZ : penghambatan IL-6 menjadi strategi terapeutik untuk mengurangi kejadian badai sitokin terkait covid-19; efikasi dan keamanannya pada pasien Covid-19 pada derajt berat msih terus diselidiki.&#13;
Baricitinib : Mekanisme obat Janus kinase inhibitor dengan menghambat proses protein fosforilasi yang terlihat dalam transduksi signal terjadinya aktivasi imun dan inflamasi. Sudah mendapat EUA dari FDA sebagai terapi tambahan untuk pasien derajat berat atau kritis. Indonesia mendapat donasi dari US Baricitinib sebanyak 9.400&#13;
dosis (4 mg peroral selama 14 hari).&#13;
Tujuan penelitian ada 2 tujuan, tujuan primer menilai perbedaan mortalitas (all-cause mortality) selama perawtan sampai hari ke-14 pada kelompok.&#13;
Tujuan Primer&#13;
Menilai perbedaan mortalitas (all-cause mortality) selama perawatan&#13;
sampai hari ke-14 pada kelompok Tocilizumab + perawatan standar&#13;
(SoC) dibandingkan kelompok Baricitinib + SoC.</mods:abstract><mods:classification authority="lcc">WC 500-590 Virus Diseases</mods:classification><mods:originInfo><mods:dateIssued encoding="iso8601">2021</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Pusat Penelitian dan Pengembangan Sumber daya dan Pelayanan Kesehatan</mods:publisher></mods:originInfo><mods:genre>Monograph</mods:genre></mets:xmlData></mets:mdWrap></mets:dmdSec><mets:amdSec ID="TMD_eprint_4316"><mets:rightsMD ID="rights_eprint_4316_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:useAndReproduction>
<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by its own author:</strong>
In self-archiving this collection of files and associated bibliographic
metadata, I grant Repositori BKPK the right to store
them and to make them permanently available publicly for free on-line.
I declare that this material is my own intellectual property and I
understand that Repositori BKPK does not assume any
responsibility if there is any breach of copyright in distributing these
files or metadata. (All authors are urged to prominently assert their
copyright on the title page of their work.)</p>

<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by someone other than its
author:</strong> I hereby declare that the collection of files and
associated bibliographic metadata that I am archiving at
Repositori BKPK is in the public domain. If this is
not the case, I accept full responsibility for any breach of copyright
that distributing these files or metadata may entail.</p>

<p xmlns="http://www.w3.org/1999/xhtml">Clicking on the <em>Deposit Item Now</em> button indicates your agreement to these
terms.</p>
    </mods:useAndReproduction></mets:xmlData></mets:mdWrap></mets:rightsMD></mets:amdSec><mets:fileSec><mets:fileGrp USE="reference"><mets:file ID="eprint_4316_12979_1" SIZE="3630124" OWNERID="http://www.badankebijakan.kemkes.go.id/repositori/id/eprint/4316/1/Laporan%20Penelitian%20Studi%20Efikasi%20dan%20Keaman%20Terapi%20Tambahan%20Obat%20Baricitinib%20pada%20Pasien%20Covid-19.pdf" MIMETYPE="application/pdf"><mets:FLocat LOCTYPE="URL" xlink:type="simple" xlink:href="http://www.badankebijakan.kemkes.go.id/repositori/id/eprint/4316/1/Laporan%20Penelitian%20Studi%20Efikasi%20dan%20Keaman%20Terapi%20Tambahan%20Obat%20Baricitinib%20pada%20Pasien%20Covid-19.pdf"></mets:FLocat></mets:file></mets:fileGrp></mets:fileSec><mets:structMap><mets:div DMDID="DMD_eprint_4316_mods" ADMID="TMD_eprint_4316"><mets:fptr FILEID="eprint_4316_document_12979_1"></mets:fptr></mets:div></mets:structMap></mets:mets>